Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BYCancer Medicine

Age‐Dependent Patterns of Cisplatin‐Induced Ototoxicity in Head and Neck Cancer: A Longitudinal Audiologic Analysis

  • C. Suzuki1
  • Y. Kishimoto1
  • M. Yamamoto2
  • N. Yamamoto3
  • M. Kitamura4
  • S. Hiraoka5
  • R. Nakashima5
  • S. Morita6
  • K. Omori1
6 affiliations
  1. 1Department of Otolaryngology‐Head and Neck Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
  2. 2Division of Behavioral Statistics, Graduate School of Human Sciences The University of Osaka Osaka Japan
  3. 3Department of Otolaryngology‐Head and Neck Surgery Kobe City Medical Center General Hospital Kobe Japan
  4. 4Department of Head and Neck Surgery Kanazawa Medical University Kahoku Japan
  5. 5Department of Radiation Oncology and Image‐Applied Therapy Kyoto University Graduate School of Medicine Kyoto Japan
  6. 6Department of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine Kyoto Kyoto Japan
Read full textPDFDOICite

Abstract

Background Cisplatin (CDDP) is a key chemotherapeutic agent used to treat head and neck cancer. Improved survival rates have increased concerns about CDDP‐induced ototoxicity, as this toxicity significantly impacts survivors' quality of life. However, the dose‐dependent and age‐related patterns of CDDP‐induced ototoxicity remain incompletely defined. Therefore, in this study, we aimed to characterize CDDP‐induced ototoxicity by tracking longitudinal hearing data and evaluating the associated factors. Patients and Methods We retrospectively analyzed a cohort of 316 patients with head and neck cancer who received CDDP‐based chemotherapy at a tertiary cancer center between January 2009 and June 2023. Hearing function was longitudinally assessed using pure‐tone audiometry (PTA) and distortion product otoacoustic emissions (DPOAE) across the cumulative CDDP dose. Multivariate logistic regression analyses were performed to identify the factors associated with ototoxicity, including the cumulative dose, age, radiotherapy, and the primary tumor site. Results At baseline, older patients exhibited substantially impaired high‐frequency hearing compared with younger patients. Across all age groups, hearing deteriorated in a dose–dependent manner following CDDP exposure. However, despite smaller apparent longitudinal threshold shifts, older patients developed clinically relevant PTA‐defined ototoxicity at lower cumulative CDDP doses than younger patients, reflecting limited auditory reserve. Contrastingly, larger threshold shifts observed in younger patients reflected greater measurable dynamic range from preserved baseline hearing rather than an increased vulnerability. DPOAE changes were attenuated in older patients, suggesting that DPOAE had reduced sensitivity for detecting CDDP‐induced ototoxicity in the presence of pre‐existing cochlear damage. Conclusion CDDP‐induced ototoxicity shows distinct age‐dependent patterns, with older patients experiencing clinically significant hearing impairment at lower cumulative doses despite smaller longitudinal changes. These findings highlight the need for age‐adapted monitoring strategies and cumulative dose‐conscious treatment planning to preserve auditory function in cancer survivors.

Related

  1. Standardizing ototoxicity monitoring for children treated with cisplatin: an urgent call to action
    Kristin Knight, Milanka Drenovak, Thorsten Langer +23
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textNeuroscienceCrossref
  2. Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network
    Nienke Streefkerk, James I. Geller, Kristin Knight +25
    Ear & HearingPeer-reviewedCC BY-NC-ND 4.0Full text2 citedNeuroscienceHALPMC
  3. Cisplatin-Induced Ototoxicity in Head and Neck Cancer: A Systematic Review of Current Evidence, Clinical Implications, and the Need for Standardized Monitoring.
    Aurora Mirabile, Alert Vukatana, Mathilda Guizzardi +3
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textNeuroscienceEurope PMC
  4. What students ask matters: Static and longitudinal questioning patterns in student–LLM dialogue and self-reported cognitive engagement
    Jingru Qu, Ling Dai, Mengjie Yin
    PLOS OnePeer-reviewedCC BY 4.0NeuroscienceStatisticsPLOS
  5. TensorPLS: an R package for exploring molecular and temporal patterns in longitudinal omics data using PLS-DA
    A. Giordano, A. Conesa, L. Balzano Nogueira
    bioRxivPreprintCC BYFull textBioinformatics & computational biologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{suzuki2026agedependent,
  title = {{Age‐Dependent Patterns of Cisplatin‐Induced Ototoxicity in Head and Neck Cancer: A Longitudinal Audiologic Analysis}},
  author = {C. Suzuki and Y. Kishimoto and M. Yamamoto and N. Yamamoto and M. Kitamura and S. Hiraoka and R. Nakashima and S. Morita and K. Omori},
  journal = {Cancer Medicine},
  year = {2026},
  month = oct,
  doi = {10.1002/cam4.72323},
  url = {https://doi.org/10.1002/cam4.72323},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Age‐Dependent Patterns of Cisplatin‐Induced Ototoxicity in Head and Neck Cancer: A Longitudinal Audiologic Analysis
AU  - C. Suzuki
AU  - Y. Kishimoto
AU  - M. Yamamoto
AU  - N. Yamamoto
AU  - M. Kitamura
AU  - S. Hiraoka
AU  - R. Nakashima
AU  - S. Morita
AU  - K. Omori
PY  - 2026
DA  - 2026/10/24
JO  - Cancer Medicine
DO  - 10.1002/cam4.72323
UR  - https://doi.org/10.1002/cam4.72323
AB  - Background Cisplatin (CDDP) is a key chemotherapeutic agent used to treat head and neck cancer. Improved survival rates have increased concerns about CDDP‐induced ototoxicity, as this toxicity significantly impacts survivors' quality of life. However, the dose‐dependent and age‐related patterns of CDDP‐induced ototoxicity remain incompletely defined. Therefore, in this study, we aimed to characterize CDDP‐induced ototoxicity by tracking longitudinal hearing data and evaluating the associated factors. Patients and Methods We retrospectively analyzed a cohort of 316 patients with head and neck cancer who received CDDP‐based chemotherapy at a tertiary cancer center between January 2009 and June 2023. Hearing function was longitudinally assessed using pure‐tone audiometry (PTA) and distortion product otoacoustic emissions (DPOAE) across the cumulative CDDP dose. Multivariate logistic regression analyses were performed to identify the factors associated with ototoxicity, including the cumulative dose, age, radiotherapy, and the primary tumor site. Results At baseline, older patients exhibited substantially impaired high‐frequency hearing compared with younger patients. Across all age groups, hearing deteriorated in a dose–dependent manner following CDDP exposure. However, despite smaller apparent longitudinal threshold shifts, older patients developed clinically relevant PTA‐defined ototoxicity at lower cumulative CDDP doses than younger patients, reflecting limited auditory reserve. Contrastingly, larger threshold shifts observed in younger patients reflected greater measurable dynamic range from preserved baseline hearing rather than an increased vulnerability. DPOAE changes were attenuated in older patients, suggesting that DPOAE had reduced sensitivity for detecting CDDP‐induced ototoxicity in the presence of pre‐existing cochlear damage. Conclusion CDDP‐induced ototoxicity shows distinct age‐dependent patterns, with older patients experiencing clinically significant hearing impairment at lower cumulative doses despite smaller longitudinal changes. These findings highlight the need for age‐adapted monitoring strategies and cumulative dose‐conscious treatment planning to preserve auditory function in cancer survivors.
SN  - 2045-7634
ER  -